Zhongheng Group announced that its subsidiary, Chongqing Lummy Pharmaceutical, has recently received the drug registration certificate for "Naloxone Hydrochloride Injection" approved and issued by the National Medical Products Administration. After examination, it meets the relevant requirements for pharmaceutical registration and is approved for registration. Lummy Pharmaceutical expressed that obtaining the drug registration certificate for Naloxone Hydrochloride Injection is conducive to further enriching the company's product line.
中恒集团子公司获盐酸纳洛酮注射液药品注册证书
Guangxi Wuzhou Zhongheng Group's subsidiary has obtained the pharmaceutical registration certificate for Naloxone Hydrochloride Injection
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.